Angion Biomedica Corp.
51 Charles Lindbergh Blvd.
Uniondale
New York
11553
United States
Tel: (516) 326-1200
Website: http://www.angion.com/
56 articles about Angion Biomedica Corp.
-
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
6/1/2023
Angion Biomedia Corp., a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10.
-
Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company.
-
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
1/17/2023
Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction.
-
Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
12/22/2022
Angion Biomedica Corp announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450.
-
Angion Provides Corporate Update and Reports Second Quarter 2022 Financial Results
8/15/2022
Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended June 30, 2022.
-
The company is readjusting its strategy as it seeks ways to preserve share value. The goal to preserve as much as the $60 million it has in cash and cash equivalents as of the year's second quarter.
-
Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value
7/25/2022
Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced it has commenced a process to explore and evaluate strategic options to enhance and preserve shareholder value.
-
Angion Biomedica Corp. discontinued a Phase II kidney disease trial while Novo Nordisk missed the mark in a NASH study.
-
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
6/29/2022
Angion Biomedica Corp. (NASDAQ:ANGN), today announced the discontinuation of JUNIPER, its Phase 2 dose-finding trial of ANG-3070, an oral tyrosine kinase inhibitor (TKI), in patients with primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN).
-
Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results
5/16/2022
Angion Biomedica Corp provided a corporate update and reported its financial results for the quarter ended March 31, 2022.
-
Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis
5/16/2022
Angion Biomedica Corp. announced U.S. Food and Drug Administration’s acceptance of an Investigational New Drug application supporting the clinical development of ANG-3070 in idiopathic pulmonary fibrosis and clearance to begin a Phase 1b study of ANG-3070 in patients with IPF.
-
Angion Announces Participation in Upcoming Investment Conference - May 12, 2022
5/12/2022
Angion Biomedica Corp. announced participation in an upcoming investment conference.
-
Angion Announces Participation in Upcoming Investment Conference - Apr 14, 2022
4/14/2022
Angion Biomedica Corp., a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced participation in an upcoming investment conference.
-
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
3/30/2022
Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today reported its financial results for full year 2021.
-
Angion Announces Participation in Upcoming Investment Conferences - Feb 28, 2022
2/28/2022
Angion Biomedica Corp., a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced participation in two upcoming investment conferences.
-
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference
1/4/2022
Angion Biomedica Corp provided a corporate update and announced the first patient has been dosed in its Phase 2 trial of ANG-3070, an oral tyrosine kinase receptor inhibitor, in patients with primary proteinuric kidney diseases.
-
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
12/10/2021
Vifor Pharma and Angion Biomedica Corp. announced results from the exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury.
-
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury
12/9/2021
Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI).
-
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
11/12/2021
Angion Biomedica Corp, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, provided a corporate update and reported financial results for the quarter ended September 30, 2021.
-
Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study
11/5/2021
Angion Biomedica Corp, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases presented four posters at the American Society of Nephrology’s Kidney Week 2021 virtual meeting, which is being held from November 4 to 7, 2021.